Prison health priorities in Burkina Faso: a cross-sectional study in the two largest detention environments in Burkina Faso.

PURPOSE: The purpose of this paper is to study the factors associated with the occurrence of diseases and beriberi among prisoners incarcerated in the two largest Remand and Correctional Facilities (RCF). DESIGN/METHODOLOGY/APPROACH: This was a cross-sectional descriptive and analytical study carried out from April 20 to May 19, 2017, in the RCFs of Ouagadougou and Bobo-Dioulasso. All prisoners who consulted and those referred to the health center by the health-care team were included in the study. Complaints and diagnosed diseases information were collected using the second version of the International Classification of Primary Care (ICPC-2). The authors used a logistic regression model to perform univariate and multivariate analyses. FINDINGS: Of the 1,004 prisoners from the two RCFs included in the study (32.6%), 966 (96%) were male. The median age was 31.6 years. The distribution of diseases diagnosed using the ICPC-2 showed a predominance of gastrointestinal tract, skin and respiratory tract diseases among 206 (19.3%), 188 (17.6%) and 184 (17.2%) prisoners, respectively. A total of 302 prisoners (30.1%) had clinical beriberi, and 80 prisoners (8%) were underweight. Being incarcerated for more than nine months was independently associated with a high risk of digestive and respiratory diseases as well as beriberi. RESEARCH LIMITATIONS/IMPLICATIONS: This study highlighted higher frequencies of digestive, skin and respiratory complaints and diseases in the two largest detention centers in Burkina Faso. These diseases are variously related to age, penal status and length of incarceration. In addition, underweight and thiamin vitamin deficiency responsible for beriberi are more frequent in adult prisoners, those not attending school, convicted prisoners and those with a length of stay in detention of more than nine months. These concrete results should help define a strategy and priority actions needed to reduce morbidity in prisons. PRACTICAL IMPLICATIONS: The actions should include the intervention of specialists in the field of common diseases in prisons, the improvement of individual hygiene conditions and environment, the improvement of the quality and quantity of the food ration, a strategy to reduce prison overcrowding. Other actions must be planned to allow specific groups such as women and minors to have access to health care that is adapted to them. Beyond the central concern of promoting the rights of prisoners and humanizing prisons, actions to improve the health of prisoners are part of an overall public health approach with its socio-economic and environmental implications. SOCIAL IMPLICATIONS: There is a need for a strong commitment from the State to develop a prison health policy that prioritizes the prevention of communicable and non-communicable diseases that are particularly prevalent in this context, without forgetting mental health and nutrition. This requires a collaboration of stakeholders based on better intersectorial communication, the implementation of a monitoring and evaluation system for the health of prisoners, an enhancement of the status of health-care providers working in prisons and an increase in the funding allocated to the health of prisoners with the mobilization of the necessary funds. ORIGINALITY/VALUE: This study uses a primary health care classification to assess the health of inmates in a prison in Africa. It contributes to the weak evidence around prison health surveillance and health profiling of prisoners in Africa.

Regression of cutaneous xerosis with emollient treatment in sub-Saharan African patients.

Emollients have proven effective in improving cutaneous xerosis in various populations; however, no clinical data are available for African patients. The observational study "Xerafrica" was conducted by dermatologists in seven sub-Saharan countries to assess the evolution of xerosis after an 8-week treatment with an emollient. Patients were children above 3 years or adults. Secondary objectives were to assess pruritus, improvement in symptoms, quality of life, satisfaction, and tolerance. An analysis of 185 patients was made. After 8 weeks of emollient treatment, the relative reduction of the "Scaling Roughness Redness Cracks" (SRRC) score was -83.9% and -80.4% in children and adults, respectively. The effect was significantly stronger when topical steroids were co-prescribed with the emollient and in patients with co-dermatosis. To a lesser extent, the effect of emollient was also observed at week 4. Similarly, pruritus and quality of life strongly improved during follow-up. Skin lesions improved in almost all patients, with a high level of satisfaction noted by both dermatologists and patients. The "Xerafrica" study addressed, for the first time, the treatment of xerosis by emollients in an African population. In this specific context, the emollient markedly reduced xerosis as soon as 4 weeks and resolved it almost totally by 8 weeks. The study confirms, under real-life conditions, the efficacy and tolerability of an emollient in improving xerosis.

[Adverse effects of antimalarial drugs spontaneously reported to pharmacovigilance national center in Burkina Faso: descriptive study and factors associated]. / Effets indesirables des antipaludiques notifies spontanement au centre national de vigilance des produits de sante au Burkina Faso: etude descriptive et facteurs associes.

AIM: To study spontaneous reporting of adverse effects of antimalarial drugs sent to pharmacovigilance national center. METHOD: A cross-sectional study was conducted to explore spontaneous reporting of adverse effects of antimalarial drugs sent to pharmacovigilance center from January 1, 2009 to December 31, 2013. RESULTS: In total 104 spontaneous reporting forms regarding antimalarial drugs were analysed. The sex ratiowas (male/female) 0,8. The majority of patients were aged over 13 years (66,3%). Self-medication and use of concomitant drug (>2) were observed in 22,1% and 46,2% of cases respectively. The artemisinin-based combination therapies (ACTs) were used in 77,8%. Several categories of adverse effects were observed among which skin and annexes disorders(34,6%), disorders of general health conditions, (29,8%), central nervous system disorders(29,8%), gastro-enterological disorders (23,0%). The most part of adverse effects was mild (67,3%).The adverse effects regarding central nervous (p=0,009)and gastro-enterological (p=0,0009) systems were significantly associated to the ACT use compared with use of other antimalarial drugs. CONCLUSION: These results show the importance to implement active surveillance of ACTs to have a safety profile in our real conditions of use.

BUT: Analyser les notifications spontanées des effets indésirables des antipaludiques transmises au centre national de pharmacovigilance. MÉTHODE: Il s'est agid'une étude transversale à visée exploratoire des notifications spontanées comportant un antipaludique, reçues au centre national de vigilance des produits de santé, du 1er janvier 2009 au 31 décembre 2013. RÉSULTATS: Au total, 104 fiches de notification ont été étudiées. Le sexe ratio hommes/femmes était égal à 0,8 et les patients de plus de 13 ans représentaient 66,3%. Les effets indésirables survenaient dans des circonstances d'automédication, de traitement concomitant de plus de deux médicaments dans 22,1% et 46,2% des cas respectivement. Les combinaisons thérapeutiques à base d'artémisinine (CTA) représentaient 77,8% des cas. Plusieurs types d'effets indésirables ont été observés, parmi lesquels les atteintes de la peau et ses annexes (34,6%), les troubles de l'état (29,8%),les troubles du système nerveux (29,8%), les troubles gastroentérologiques (23,0%). Les effets indésirables étaient le plus souvent modérés (67,3%). Ceux se rapportant au système nerveux (p=0,009) et à l'appareil gastroentérologique(p=0,0009) étaient associés significativement à l'utilisation d'une CTA. CONCLUSION: Ces résultats montrent la nécessité d'une surveillance plus intense des CTA pour mieux décrire leur profil de tolérance dans nos conditions réelles d'utilisation.

Stevens-Johnson syndrome and toxic epidermal necrolysis in sub-Saharan Africa: a multicentric study in four countries.

OBJECTIVE: The purpose of this study was to document the clinical profile, etiologies, and outcomes of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) in hospitals in four sub-Saharan African countries. PATIENTS AND METHODS: A retrospective study on cases of SJS/TEN treated in dermatology departments and/or intensive care units in four sub-Saharan African countries (Benin, Burkina Faso, Central African Republic, and Togo) from 2000 to 2010. The study focuses on variables such as age, sex, type of SJS/TEN, epidermal detachment of the skin surface, HIV status, drug(s) involved, and outcomes (death and sequelae). RESULTS: This study identified 177 cases of SJS/TEN from 2000 to 2010: 129 with SJS; 37 TEN; and 11 overlapping SJS/TEN. The average age of patients was 32.3 ± 15.4 years, and the sex ratio (M/F) was 0.6. HIV serology was positive in 69 (54.8%) of the 126 patients tested. Antibacterial sulfonamides (38.4%) were the most commonly used drugs followed by nevirapine (19.8%) and tuberculosis drugs (5.6%). We recorded 22 deaths (i.e. six cases of SJS, 15 of TEN, and one of overlapping SJS/TEN). Of the 22 patients who died, 16 were infected with HIV; among them, seven had an opportunistic infection (four cases of cerebral toxoplasmosis and three of pulmonary tuberculosis). Twenty-seven cases of sequelae were noted with a large part of eye complications. CONCLUSION: This study has highlighted: (i) the high proportion of patients infected with HIV among patients who had SJS/TEN in sub-Saharan Africa; (ii) the high frequency of antiretroviral drugs as new SJS/TEN causes in sub-Saharan Africa; and (iii) the impact of HIV infection on morbidity and mortality of these affections.